Abvc Biopharma ABVC Cash Flow Statement (2010-2026)

NASDAQ ABVC
$0.98 +0.01 (+0.64%)
At close: Sep 10, 2026 · 4:00 PM EDT
Reported Financials

Abvc Biopharma Quarterly Cash Flow Statement

Periods 58 quarters
Latest Jun 2026

Abvc Biopharma reported cash from operations of -$0.24M and free cash flow of -$0.24M for the quarter ended Jun 2026, up 72.7% year over year. This cash flow statement covers 58 quarters of results from Jun 2010 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow Statement Jun2010 Sep2010 Dec2010 Mar2011 Jun2011 Sep2011 Dec2011 Mar2012 Jun2012 Sep2012 Dec2012 Mar2013 Sep2014 Dec2014 Sep2015 Dec2015 Mar2016 Jun2016 Sep2016 Dec2016 Mar2017 Jun2017 Sep2017 Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Operating Activities
Net Income
-1.89M-6.90M-6.09M-1.95M-3.78M-4.50M-1.90M-2.32M-3.37M-0.70M-2.93M-1.05M-0.49M-0.80M-0.75M-2.33M-2.08M-3.02M-1.34M-0.64M
Share-based Compensation
0.23M4.38M4.69M0.23M0.23M1.89M0.37M0.23M0.82M-0.87M2.59M0.28M0.26M0.36M0.21M1.57M1.41M0.79M0.51M
Deferred Taxes
0.13M0.57M-0.09M-0.08M0.14M0.90M-0.12M0.15M
Gains from Investment Securities
Asset Writedowns and Impairment
-0.34M1.42M
Cash from Operations
-2.22M-2.52M-2.99M-3.43M-0.51M-0.46M-1.50M-0.90M-1.36M-0.43M-0.96M-0.21M0.06M-0.70M-0.54M-0.89M-0.96M-0.59M-0.89M-0.24M
Depreciation, Depletion & Amortization
Amortizatization of Intangibles
0.10M0.10M0.10M-0.13M0.11M0.07M0.09M0.21M0.09M0.08M
Depreciation & Amortization (CF)Depreciation & Amortization
0.00M0.00M0.01M0.01M0.01M0.01M0.01M0.01M0.01M
Change in Working Capital
Change in Receivables
-0.05M-0.05M505.000.01M0.02M0.58M-0.11M-0.07M-0.01M-0.04M
Change in Inventory
-0.03M-0.00M64.00-0.00M0.01M
Change in Account Payables
0.20M-0.50M0.06M0.02M-0.02M0.18M0.38M-0.03M-0.50M-0.03M0.13M0.02M0.09M
Change in Accured Expenses
-0.54M0.17M-0.11M0.09M-0.08M1.71M-0.15M0.68M0.12M-0.01M-0.04M0.13M-0.04M0.11M0.04M-0.02M-0.03M0.16M-0.01M0.05M
Change in Taxes
-0.02M0.01M-0.01M-0.01M
Other Working Capital Changes
0.20M-0.20M-0.10M-0.10M-0.10M0.13M-0.11M-0.07M-0.10M-0.20M-0.10M-0.11M
Investing Activities
Change in Net Loans
-0.04M0.51M0.09M
Capital Expenditures
0.09M0.02M0.00M89.00-0.42M
Change in Acquisitions & Divestments
Cash from Investing Activities
-0.81M0.43M-0.09M-0.02M-1.52M-0.08M-0.07M0.15M0.04M-0.51M-0.03M0.05M-0.10M
Financing Activities
Other financing activities
-0.02M0.39M0.34M0.21M0.41M2.37M0.53M0.32M-0.22M
Debt Issuance and Repayment
Long-Term Debt Issuances
3.21M-0.03M-1.82M0.11M0.28M0.32M0.05M-0.09M0.05M0.49M-0.10M0.26M
Long-Term Debt Repayments
1.00M0.15M
Short-Term Debt issuances
1.00M0.03M0.03M0.03M0.03M0.03M0.66M0.03M
Short-Term Debt repayments
Change in Capital Stock
Shares Issued
Net Shares Issued and Repurchased
0.08M
Net Equity Issued and Repurchased
4.24M0.25M-0.25M0.69M
Misc.
Cash from Financing Activities
5.82M4.25M0.60M-0.25M2.21M-0.03M1.66M0.04M0.92M0.80M-0.08M0.34M0.43M1.93M1.20M1.08M-0.34M0.23M
Exchange Rate Effect
0.00M-0.04M-0.05M-0.05M-0.20M0.22M-0.31M0.32M0.15M-0.17M-0.03M-0.01M0.00M0.00M0.01M-0.05M0.05M0.01M0.00M0.01M
Change in Cash
2.79M2.12M-3.13M0.17M-1.63M-0.58M0.40M-1.05M0.38M-0.40M-0.06M0.08M0.03M0.09M-0.10M0.32M-0.22M0.47M-1.19M-0.11M
Free Cash Flow
-2.22M-2.52M-3.09M-3.45M-0.52M-0.46M-1.50M-0.90M-0.94M-0.43M-0.96M-0.21M0.06M-0.70M-0.54M-0.89M-0.96M-0.59M-0.89M-0.24M
Net Cash Flow
2.79M2.16M-3.09M-3.45M-1.43M-0.80M0.71M-0.93M0.22M-0.24M-0.03M0.59M0.02M-0.37M-0.11M1.03M-0.27M0.46M-1.19M-0.12M